ati-9242
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02824666)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 1a (5-HT1a) receptorANTAGONIST
HTR1A antagonist
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ati-9242
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02824666 | Phase 1 | Jun 1, 2016 | Braeburn Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Braeburn Pharmaceuticals | For profit | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1